DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma

Inclusion Criteria: * 18-80 years old; * Histologically confirmed with Hepatocellular Carcinoma at stage I-II; * Patients who can accept Transcatheter Arterial Chemoembolization ; * Patients who have a life expectancy of at least 3 months; * Patients who have a Child-Pugh:A/B; .Eastern Cooperative Oncology Group (ECOG) performance status was 0-2. Exclusion Criteria: * White blood cell \<3 x 10\^9/L,Platelet count \<75 x 10\^9/L;BUN and Cr more than normal limits on 3.0 times ; * Known or suspected allergy to the investigational agent or any agent given in association with this trial; * Pregnant or lactating patients; * Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection; * Patients who are suffering from serious autoimmune disease; * Patients who had used long time or are using immunosuppressant; * Patients who had active infection; * Prior use of any anti-cancer treatment in 30 days; * Now or recently will join another experimental clinical study ; * History of organ allograft; * Other situations that the researchers considered unsuitable for this study